{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"}],"units":"Participants"}],"description":"DLT was defined as an adverse event meeting any of the following that occurred during the DLT evaluation period in any participants given BBI608 with the causal relationship to BBI608 assessed as \"Definite,\" \"Probable,\" or \"Possible.\" The severity of adverse events was graded according to the CTCAE v4.0-JCOG.\n\n* Grade 4 neutropenia persisting for ≥ 7 days\n* Grade ≥ 3 febrile neutropenia persisting for ≥ 5 days\n* Grade 3 thrombocytopenia requiring platelet transfusions, grade 4 thrombocytopenia\n* Grade ≥ 3 non-hematotoxicity except the following:\n\n  1. Inappetence, nausea, vomiting and electrolyte abnormality which, within 3 days of onset, improved to grade ≤ 2 or resolved after appropriate treatment\n  2. Diarrhoea and fatigue which, within 5 days of onset, improved to grade ≤ 2 or resolved after appropriate treatment\n* Other clinically significant signs in the opinion of the investigator","groups":[{"description":"Participants orally received BBI608 (480 mg) twice daily plus intravenously received Pem (500 mg/m2) and CDDP (75 mg/m2) on Day 3 in only Cycles 1 and on Days 1 in Cycles 2 and subsequent cycles.\n\nPremeditation with folic acid and vitamin B12 was given to reduce occurrence of serious adverse drug reactions, with reference to the package insert for Pem. Each cycle was defined as 21 days.","id":"OG000","title":"MPM or NSCLC: BBI608 + Pem + CDDP (Phase 1 Part)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"DLT evaluable population (3 participants with NSCLC in Phase 1 part)\n\n1 participant with MPM was excluded from DLT evaluable population because the BBI608 treatment compliance rate during DLT evaluation period did not meet the rate of 80% which of assessable for DLT and no adverse events assessed as DLT occurred.","reportingStatus":"POSTED","timeFrame":"From Day 1 of Cycle 1 to Day 24 pre-dose examination (23 days)","title":"Phase 1 Part: Number of Participants With Dose-limiting Toxicities (DLTs)","type":"PRIMARY","unitOfMeasure":"Participants"}